Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
going to add this site to my watchlist:
https://omnihealth.blog/
gotta stay on top of potential leads/updates.
i know Andrey likes to blog so this is interesting....
no connection "yet" but because of the name and knowing hes a blogger its being added to my list of monitored sites.
i think its plausible we hear after this court case settles. it is my opinion the silence is due to this court battle. the reason i think this is because of the timely coincidence of the case and going dark.
looks like its just omni now on the court case.
court case update 09/01/2020:
Andrey removed from case
09/18/2020 next court meeting.
Here comes the big money:
https://scitechdaily.com/pharma-aims-to-make-a-better-cbd-up-to-50-times-more-potent/amp/
you can bet that the DEA will cave when the wealth of pharma influence comes into play that companies like omnihealth are poised to benefit moreover our product relivatrol has tested phase 1 really well that's ripe for a CBD big pharma partner post phase 2 "currently underway"
gotta be federally. otherwise its meaningless. DEA/FDA.
Omni poised for greatness post legalization: https://thehill.com/opinion/healthcare/515299-one-cure-for-an-ailing-american-economy-legalize-cannabis?amp
2 weeks away from next court update. 09/18/2020
from the other side of the isle i been waiting for proof of malecon sale from anyone.
AND! AND! REAL PHARMA STUDIES IN PHASE 2 STUDIES! DON'T FORGET THOSE!
https://insights.ovid.com/obstetrics-gynecology/obsgy/2020/05/001/novel-therapeutic-management-post-episiotomy-pain/475/00006250
The relivatrol study makes it realistic thought process
the best farts are silent but deadly... thus omnihealth operating form 15 status operating out of the spot light is destined for great things.
OMNI went dark to PROTECT THEIR i.p.
he hasn't stated anything pertaining to the ware abouts of andrey or the status of the company.
any DD questions I'll do my best to help.
I'm genuinely excited about the pharmacuetical potential here.
wasn't I, BEEN LOADED DOWN HERE FOR WEEKS. multi millions long.
yes sir, looking forward to seeing phase 2 study results for relivatrol.
they are currently underway.
https://insights.ovid.com/obstetrics-gynecology/obsgy/2020/05/001/novel-therapeutic-management-post-episiotomy-pain/475/00006250
relivatrol goes up against competition:
official study:
https://insights.ovid.com/obstetrics-gynecology/obsgy/2020/05/001/novel-therapeutic-management-post-episiotomy-pain/475/00006250
Quote:
talk to Andrew real nice guy he's on social platforms: http://voyagemia.com/interview/meet-andrew-damian-forbes-author-wealth-wheel-ebook-founder/
to answer your triple 0's comment a form 15 will crash any otc for many reasons. in omnis case a quite period for intellectual property protection and product reformulations to include cannabinoids. they secured a 1,000,000 bridge loan to get them through the quite period see annuals for more info.
Here is some due diligence:$OMHE
cheers,
ticker symbol: $OMHE
entity name: OMNIHEALTH, INC
relivatrol physician endorsement: https://www.dailymotion.com/relivatrol/videos?sort=visited
relivatrol study with larger ones underway:
https://insights.ovid.com/obstetrics-gynecology/obsgy/2020/05/001/novel-therapeutic-management-post-episiotomy-pain/475/00006250
and yet this cannin article is old and out of date
and lacks recent events/findings. it only points out 1 issue communication. however that issue is subdued with all of the information provided like these items:
study Publication Date: May 2020
https://insights.ovid.com/obstetrics-gynecology/obsgy/2020/05/001/novel-therapeutic-management-post-episiotomy-pain/475/00006250
A Novel Therapeutic in the Management of Post-Episiotomy Pain [02M]
Yisroel Grabie;Nawshin Jamil;Joseph Schwob;Arkady Uryash;
+ Author Information
Check Ovid for access View on Journal Site
Abstract
INTRODUCTION:
Although rates of episiotomy are declining, post-episiotomy pain remains a complication in obstetric care. Current management includes NSAIDs and Benzocaine, but the use of Benzocaine has been linked to iatrogenic methemoglobinemia, with greatest risk in newborns. We hypothesized that a novel drug formulation, currently being investigated in diabetic neuropathy, can be used to attenuate post-episiotomy pain.
METHODS:
This pilot study was conducted in an outpatient obstetrics clinic on postpartum women aged between 18 and 39, who underwent vaginal delivery with episiotomy. Spray bottles with the investigational product were distributed to the patients to use without regulation. A survey to assess post-episiotomy pain using the Visual Analog Scale (VAS) was administered to the patients. Pain attenuation, time to pain attenuation, and quality of pain were measured.
RESULTS:
The cohort consisted of 25 women (including 5 non-responders). In responders, pain was attenuated by 4.0 scale units. Average time to analgesia was 9.25. Average pain ratings after treatment were compared to average pain ratings before treatment using a unidirectional paired sample t test (df=24). The average pain ratings for the entire cohort after administration of Relivatrol© were significantly lower than average pain rating prior to administration t (24)=7.41, P<.0001.
CONCLUSION:
2 types of products one with other without cbd.
just to make my thought clear on whats coming.
the non cbd they can push now.
the cbd based will wait for other reasons like legal/banking reasons.
It's a medical Cannabinoid product so it gets special treatment at the FDA because it also falls into a higher focus area of pain management by the FDA. it will be sold through proper legal channels as a pain cream in states where medical cannabis use is already underway.
But yes it can go toe to toe with the biggest names in the pain cream market at your Walgreens or Walmart. they're pitch deck clearly targets such items.
Keep in mind they can proceed with other items like this study without CBD in it and can market it that way as well.
so a study showing its viability already and without infused CBD is good news. brings real merit to they're product I.P. and scientific board.
Stage 1&2 "smaller" studies are on us looking for stage 3 partner is my understanding depending on product in question. I.E. relieveMD dr.cbd reformulations.
but yes this is all stuff coming to fruition previously stated/suggested.
New relivatrol ad:
daily motion relivatrol ad
Looking forward to Friday. another patient week in the bag.
FDA COMMENTS ON CBD PRODUCTS:
OMNIHEALTH INC SCINTIFIC ADVISORY BOARD:
https://www.fda.gov/news-events/fda-brief/fda-brief-fda-issues-draft-guidance-encourage-cannabis-related-clinical-research
san diego court case update:pending dismissal.
https://drive.google.com/file/d/1Jp-v8ARF1umcexr6tKMssFOMA9OVw7D7/view?usp=sharing
CASE IS ON THE VERGE OF DISMISSAL..
latest court developement posted:
https://roa.sdcourt.ca.gov/roa/faces/userdocs/f1035626216498da3340be3f37ce/37-2018-00039329-CU-BC-CTL_ROA-98_08-14-20_Order_to_Appear_SD_1597712198967.pdf
any link issues please advise. found new way of posting this info.
and patents don't forget those.
best left out fact: SAVES THEM 100,000's IN FILING FEE'S